Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.38 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | ARG1 | P05089 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ARG2 | P78540 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4121666 | 0.80 | MEN1 (0.53) | MEN1KMT2A | |
| SCHEMBL4125694 | 0.79 | TDP1 (0.38) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL12017885 | 0.76 | DPP4 (0.37) | DPP4FAPMEN1KMT2A | |
| SCHEMBL11634507 | 0.73 | HPGD (0.35) | MEN1KMT2A | |
| SCHEMBL4178226 | 0.72 | ALDH1A2 (0.43) | MEN1KMT2A | |
| SCHEMBL12019279 | 0.71 | CHRNB4 (0.36) | MEN1KMT2A | |
| SCHEMBL2735577 | 0.71 | DPP4 (0.46) | DPP4DPP7ARG1KMT2A | |
| SCHEMBL8034816 | 0.71 | DPP4 (0.46) | DPP4DPP7ARG1KMT2A | |
| SCHEMBL24576792 | 0.69 | TAAR1 (0.39) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL24576750 | 0.69 | TAAR1 (0.39) | DPP4FAPDPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431565-B2 | Substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | claimed |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CNR1, CNR2, TRPV1 | DPP4 4359/4885FAP 2952/4885DPP8 3805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.